Drag a card by its title · ⚙ to size, swap or remove

The company

Geospace Technologies Corporation

GEOS · Nasdaq

Health CareLife-science toolsNot moving yet

GEOS stood above a rising 150-day average in 9 of the last 52 weekly readings, and has been out of that trend for the last 39 weeks. It is 40.3% below that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 39
Industry in uptrend: 54% +4 in 4 wk
Insider buys, 12 months: $0
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 78 (-3)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 9 of 52 weeks.

20 Apr – 19 Oct

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0

Sale orders, 12 months0

Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders78-3 on the quarter

New · exited18 · 21

Reported value$28.0M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
GRACE & WHITE INCadded · filed 17 Jul 2026	673,236$4.6M	+200,035+42.3%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026	515,067$3.5M	-61,965−10.7%
DIMENSIONAL FUND ADVISORS LPreduced · filed 11 Aug 2026	392,423$2.7M	-98,593−20.1%
MARSHALL WACE, LLPadded · filed 13 Aug 2026	301,916$2.0M	+113,110+59.9%
BlackRock, Inc.added · filed 7 Aug 2026	231,765$1.6M	+6,197+2.7%
US BANCORP \DE\added · filed 12 Aug 2026	212,766$1.4M	+85,632+67.4%
SEI INVESTMENTS COreduced · filed 14 Aug 2026	199,365$1.3M	-211,541−51.5%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026	164,180$1.1M	+12,026+7.9%
STATE STREET CORPadded · filed 7 Aug 2026	163,075$1.1M	+26,222+19.2%
De Lisle Partners LLPunchanged · filed 12 Aug 2026	147,133$998K	00.0%

31 Mar 2023 – 30 Jun 2026

News

No headline names it lately.

Everyone who traded it

Edgar R. Giesinger Jr. Director · last 9 Feb 20260 · 0

Richard F. Miles Director · last 9 Feb 20261 · 4

Thomas L. Davis Director · last 9 Feb 20262 · 2

Richard James Kelley President & CEO · last 5 Dec 20250 · 0

Robert L. Curda Vice President & CFO · last 5 Dec 20250 · 0

Ronald Todd Bushey Chief Technical Officer · last 2 Dec 20250 · 0

Margaret Ashworth Director · last 9 Feb 20250 · 0

Stephen C. Jumper Director · last 9 Feb 20250 · 0

Walter R. Wheeler Director · last 9 Feb 20252 · 1

Robbin B. Adams SVP & Chief Technical Officer · last 21 Nov 20240 · 21

Gary D. Owens Director · last 7 Feb 202420 · 47

Tina M. Langtry Director · last 9 Feb 20234 · 0

Same industry

OABI OmniAbLeading+67%

TXG 10x GenomicsLeading+59%

AVTR AvantorLeading+45%

ILMN IlluminaLeading+44%

RVTY RevvityLeading+35%

CRL Charles River Laboratories InternationalLeading+34%

MASS 908 DevicesLeading+32%

IQV IQVIA HoldingsLeading+27%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 30 Sep 202529.7%

Operating profit marginFY 2025 · to 30 Sep 2025-10.2%

Free cash flow marginFY 2025 · to 30 Sep 2025-27.3%

Return on capital employedFY 2025 · to 30 Sep 2025-8.8%

Interest coverFY 2025 · to 30 Sep 2025-66.77×

Research spendFY 2025 · to 30 Sep 202517.1%

Share count trendFY 2025 · to 31 Oct 20250.0%

Cash and equivalentsFY 2025 · to 30 Sep 2025$26.3M

Free cash flowFY 2025 · to 30 Sep 2025−$30.2M

Analyst forecasts

No analyst forecasts yet.